

Freedom of Information Request: Our Reference CTMUHB_105_22

You asked:

I am investigating the use of targeted therapies in blood-related cancers. Could you please tell me how many patients have you treated in the last 3 months for Multiple Myeloma? Further, how many have received the following treatments?

We can confirm that the Health Board does hold this information. However, to release the specific information in the way that you have requested would mean disclosure of low numbers.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

However, in order to fulfil our obligation under Section 16 of the Act to provide advice and assistance, in the below table, where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Treatment	Patients in last 3 months
Bortezomib [Velcade] and Dexamethasone	**
Bortezomib [Velcade], Thalidomide and Dexamethasone [known as VTD]	5
Bortezomib [Velcade], Cyclophosphamide/Melphalan and Dexamethasone/Prednisolone [known as VCD or VMP]	11
Lenalidomide [Revlimid] monotherapy	**
Lenalidomide [Revlimid] and Dexamethasone	14
Lenalidomide [Revlimid], Bortezomib [Velcade] and Dexamethasone	**
Lenalidomide [Revlimid], Melphalan and Prednisolone	**
Thalidomide, Cyclophosphamide/Melphalan, and Dexamethasone/Prednisolone [known as MPT or CTD]	**
Bortezomib [Velcade] monotherapy	**
Carfilzomib [Kyprolis] and Dexamethasone	**
Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and Dexamethasone [known as KRD]	**
Daratumumab [Darzalex], Velcade [Bortezomib] and Dexamethasone [known as DVD]	15
Daratumumab [Darzalex], Velcade [Bortezomib], Thalidomide and Dexamethasone [known as Dara-VTD]	**
Daratumumab [Darzalex], Lenalidomide [Revlimid] and Dexamethasone	**
Daratumumab [Darzalex], Pomalidomide [Imnovid] and Dexamethasone (DaraPd)	**
Daratumumab [Darzalex] monotherapy	**

Isatuximab [Sarclisa], Pomalidomide [Imnovid] and Dexamethasone [known as IsaPd]	**
Isatuximab [Sarclisa], Carfilzomib [Kyprolis] and Dexamethasone [known as IsaKd]	**
Ixazomib [Ninlaro], Lenalidomide [Revlimid] and Dexamethasone [known as IRD]	**
Pomalidomide [Imnovid] and Dexamethasone	**
Panobinostat [Farydak], Bortezomib [Velcade] and Dexamethasone	**
Any other systemic anti-cancer treatment	**